<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03508141</url>
  </required_header>
  <id_info>
    <org_study_id>FEISTY Jnr 1</org_study_id>
    <nct_id>NCT03508141</nct_id>
  </id_info>
  <brief_title>Fibrinogen Early In Severe Trauma studY Junior</brief_title>
  <acronym>FEISTY Jnr</acronym>
  <official_title>Fibrinogen Concentrate vs Cryoprecipitate in Traumatic Haemorrhage in Children: A Pilot Randomised Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Gold Coast Hospital and Health Service</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Emergency Medicine Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Blood Authority</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Australian Red Cross</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Gold Coast Hospital and Health Service</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      1. Haemorrhage in severe trauma is a significant cause of mortality and is potentially the
           most preventable cause of death in paediatric trauma patients

        2. Trauma Induced Coagulopathy (TIC) is a complex coagulopathy associated with severe
           trauma

        3. Hypo/dysfibrinogenaemia plays an important role in TIC

        4. Early replacement of fibrinogen may improve outcomes

        5. Fibrinogen replacement is potentially inadequate in standard fixed ratio Major
           Haemorrhage Protocols (MHP) utilising Plasma and/or Cryoprecipitate

        6. The majority of centres utilise cryoprecipitate for additional fibrinogen
           supplementation as part of a MHP

        7. Cryoprecipitate administration is often delayed (between 60 - 120 minutes) in a fixed
           ratio MHP

        8. It is clear early intervention in severe traumatic haemorrhage is associated with
           improved outcomes - CRASH 2 and PROPPR studies

        9. Increasing interest in the use of Fibrinogen Concentrate (FC) in severe bleeding but not
           supported by high level evidence

       10. Benefits of FC - viral inactivation, known dose, easily reconstituted, can be
           administered quickly in high dose and stored at room temperature in the trauma
           resuscitation bay

      12. No previous studies comparing FC and Cryoprecipitate in bleeding paediatric trauma
      patients 13. Fibrinogen supplementation will be guided by an accepted ROTEM targeted
      treatment algorithm 14. Pilot, multi-centre randomised controlled trial comparing FC to
      Cryoprecipitate (current standard practise in fibrinogen supplementation) 15. Hypothesis:
      Fibrinogen replacement in severe traumatic haemorrhage can be achieved quicker with a more
      predictable dose response using Fibrinogen Concentrate compared to Cryoprecipitate 16. It is
      imperative that robust and clinically relevant trials are performed to investigate fibrinogen
      supplementation in paediatric trauma patients before widespread adoption makes performing
      such studies unfeasible
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">June 1, 2018</start_date>
  <completion_date type="Anticipated">December 1, 2020</completion_date>
  <primary_completion_date type="Anticipated">June 1, 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Time to administration of fibrinogen replacement from time of identification of hypofibrinogenaemia requiring fibrinogen replacement</measure>
    <time_frame>3 Hours</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Transfusion Requirements</measure>
    <time_frame>Up to 48 hours after Trauma Unit presentation</time_frame>
    <description>In number of units of Packed Red Blood Cells, Plasma, FC, Cryoprecipitate, Platelets, Prothrombin Complex Concentrate at 4, 6, 24, 48hrs</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of bleeding episode or time until surgical control</measure>
    <time_frame>It is anticipated that haemorrhage control will be achieved within 12 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Intensive Care Unit LOS</measure>
    <time_frame>1 Year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hospital LOS</measure>
    <time_frame>1 Year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse Events</measure>
    <time_frame>1 Year</time_frame>
    <description>Transfusion related adverse events, Sepsis, Multiple Organ Failure, Acute Renal Failure, Symptomatic Thromboembolic Complications</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>All Cause Mortality</measure>
    <time_frame>Up to 90 Days</time_frame>
    <description>Mortality at 4, 6, 24 hours and up to 90 days</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Functional Outcomes GOS-E Paediatrics</measure>
    <time_frame>Up to 90 Days</time_frame>
    <description>Functional Outcome Measures at 60 and 90 Days</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">44</enrollment>
  <condition>Trauma</condition>
  <condition>Hemorrhage</condition>
  <condition>Coagulopathy</condition>
  <condition>Pediatrics</condition>
  <arm_group>
    <arm_group_label>Fibrinogen Concentrate</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Fibrinogen Replacement using Fibrinogen Concentrate as per ROTEM (FIBTEM) FIBTEM A5 0mm = 60mg/kg FC FIBTEM A5 1-4mm = 50mg/kg FC FIBTEM A5 5-6mm = 40mg/kg FC FIBTEM A5 7-8mm = 30mg/kg FC FIBTEM A5 9-10mm = 20mg/kg FC</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cryoprecipitate</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Fibrinogen Replacement using Cryoprecipitate as per ROTEM (FIBTEM) FIBTEM A5 0mm = 6ml/kg Cryoprecipitate FIBTEM A5 1-4mm = 5ml/kg Cryoprecipitate FIBTEM A5 5-6mm = 4ml/kg Cryoprecipitate FIBTEM A5 7-8mm = 3ml/kg Cryoprecipitate FIBTEM A5 9-10mm = 2ml/kg Cryoprecipitate</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fibrinogen Concentrate</intervention_name>
    <description>Experimental</description>
    <arm_group_label>Fibrinogen Concentrate</arm_group_label>
    <other_name>Riastap</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cryoprecipitate</intervention_name>
    <description>Comparator</description>
    <arm_group_label>Cryoprecipitate</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Child affected by trauma (3 months to 18 years)

          2. Judged to have significant haemorrhage OR predicted to require significant transfusion
             by the treating clinician

          3. Activation of Local MHP or transfusion of emergency red blood cells (Pre-hospital or
             at Trauma Centre)

        Exclusion Criteria:

          1. Injury judged incompatible with survival

          2. Randomisation unable to occur within 6 hours of hospital admission

          3. Pregnancy

          4. Known personal or parental objection to blood products

          5. Known coagulation disorder (i.e. haemophilia, von Willebrand disease)

          6. Previous dedicated fibrinogen replacement this admission

          7. Pre-Trauma Centre dedicated fibrinogen replacement

          8. Participation in competing study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>3 Months</minimum_age>
    <maximum_age>18 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Shane George, MBBS</last_name>
    <role>Principal Investigator</role>
    <affiliation>Lady Cilento Children's Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>James Winearls, MBBS</last_name>
    <phone>+61756875684</phone>
    <email>james.winearls@health.qld.gov.au</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Elizabeth Wake, BN</last_name>
    <phone>+61756874149</phone>
    <email>elizabeth.wake@health.qld.gov.au</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Royal Brisbane and Women's Hospital</name>
      <address>
        <city>Brisbane</city>
        <state>Queensland</state>
        <zip>4029</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lady Cilento Children's Hospital</name>
      <address>
        <city>Brisbane</city>
        <state>Queensland</state>
        <zip>4101</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Dr George, MBBS</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Princess Alexandra Hospital</name>
      <address>
        <city>Brisbane</city>
        <state>Queensland</state>
        <zip>4102</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gold Coast University Hospital</name>
      <address>
        <city>Gold Coast</city>
        <state>Queensland</state>
        <zip>4215</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Townsville Hospital</name>
      <address>
        <city>Townsville</city>
        <state>Queensland</state>
        <zip>4814</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
  </location_countries>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 23, 2018</study_first_submitted>
  <study_first_submitted_qc>April 16, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">April 25, 2018</study_first_posted>
  <last_update_submitted>April 16, 2018</last_update_submitted>
  <last_update_submitted_qc>April 16, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 25, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Gold Coast Hospital and Health Service</investigator_affiliation>
    <investigator_full_name>Dr James Winearls, BSc (Hons), MBBS, MRCP, FCICM</investigator_full_name>
    <investigator_title>Dr James Winearls, Consultant Intensivist GCUH</investigator_title>
  </responsible_party>
  <keyword>Fibrinogen Concentrate</keyword>
  <keyword>Cryoprecipitate</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hemorrhage</mesh_term>
    <mesh_term>Blood Coagulation Disorders</mesh_term>
    <mesh_term>Hemostatic Disorders</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

